A Phase 3 interventional study of NVA237 and Placebo in Chronic Obstructive Pulmonary Disease, sponsored by Novartis Pharmaceuticals. Completed at 59 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2015-03-11.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 25th largest by enrollment, is one of 11 that started in 2012, is one of 33 in phase 3, and was the 30th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Germany, United Kingdom
Ages 40–80
AstraZeneca · Sites in United States, Argentina, Australia and 34 more countries
Ages 40–80
By country, each count listing its studies:
Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 21 · Phase 3 33 · Phase 4 11
First in 2005; this study’s year is marked. 11 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 432 is above the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 152 across the 73 interventional studies. Of the 67 that completed or were terminated, 49 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
67 of 73 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
117 studies in Pulmonary Disease, Chronic Obstructive by Novartis: none open now, none under way, none of them phase 3. Of 110 finished, 94 (85%) have results posted.
Among the 117 studies in Pulmonary Disease, Chronic Obstructive by Novartis, this one is the 41st largest by enrollment of the 116 interventional ones that give a count, is one of 22 that started in 2012, is one of 59 in phase 3, and was the 79th registered.
Novartis’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2003.
1 of the studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 117 in Pulmonary Disease, Chronic Obstructive:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study serves to determine whether the treatment of patients with stable, symptomatic Chronic Obstructive Pulmonary Disease (COPD) with the investigational drug NVA237 is efficient and safe. The efficacy and safety of the drug will be tested against a placebo treatment. The primary criterion to assess efficacy will be the difference between the serial lung function measurements of patients who have been treated for 12 weeks with NVA237 versus those that have received placebo treatment for 12 weeks. A serial lung function measurement (FEV1 testing) will be conducted and the "area under the curve" will be the measure for the ability to breathe.
Inclusion criteria: 1. Patients with stable, symptomatic (COPD) with airflow obstruction of level 2 and 3 according to the current Global initiative for chronic Obstructive Lung Disease (GOLD) strategy (2011). 2. Patients with (FEV1) ≥ 30% and \<80 % of the predicted normal, and FEV1/FVC \< 0.70 when measured 45 min after the inhalation of 84 µg ipratropium bromide.
Exclusion criteria:
Other protocol-defnied inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NVA237 will be inhaled from a single-dose dry powder inhaler for a period of 12 weeks
Drug: NVA237
Placebo will be inhaled from a single-dose dry powder inhaler for a period of 12 weeks
Drug: Placebo
NVA237 (Glycopyrronioum bromide) as a powder for inhalation in single-dose capsules
Placebo powder for inhalation in single-dose capsules (matching those for NVA237).
Change From Baseline in Standardized Area Under the Curve for Forced Expiratory Volume in One Second Post Dosing
The standardized Area Under the Curve (AUC) for Forced Expiratory Volume in one second (FEV1) post dosing (FEV1 AUC) is measured at week 12 of treatment. Serial lung function measurements are taken at the following time points following dosing at week 12 to calculate the FEV1 AUC: 5 min, 15 min, 1:00 h, 2:00 h, 4:00 h, 6:00 h, 8:00 h, and 11:55 h after the morning dose. The primary endpoint was the change from baseline in FEV1 AUC0-12h following the morning dose at Week 12 (defined as the mean FEV1 change from baseline (CFB) over 5 min to 11 h 55 mins divided by 11 h 50 mins). Where the FEV1 AUC is smaller than at baseline, a negative value can occur
Time frame: Week 12
Change From Baseline in Standardized Area Under the Curve (AUC(0-12h)) for Forced Expiratory Volume in One Second Post Dosing
The standardized Area Under the Curve (AUC) for Forced Expiratory Volume in one second (FEV1) post dosing (FEV1 AUC) is assessed at day 1 of treatment. Serial lung function measurements are taken at the following various time points post dosing at day 1 to calculate the FEV1 AUC: 5 min, 15 min, 1:00 h, 2:00 h, 4:00 h, 6:00 h, 8:00 h, and 11:55 h after the morning dose. .The endpoint was the change from baseline (CFB) in FEV1 AUC0-12h following the morning dose at day 1 (defined as the mean FEV1 change from baseline over 5 min to 11 h 55 mins divided by 11 h 50 mins). Where the FEV1 AUC is smaller than at baseline, a negative value can occur.
Time frame: Day 1
Change From Baseline in Standardized Area Under The Curve for Forced Expiratory Volume in One Second for Different Time Spans Post Dosing
The standardized Area Under the Curve (AUC) for Forced Expiratory Volume in one second (FEV1FEV1) is assessed for different time spans (0-4 h, 4-8 h, 8-12 h) within the overall serial measurement post dosing (FEV1 AUCs Time Spans), at day 1 and at week 12 of treatment. Serial lung function measurements are taken at various the following time points post dosing on day 1 and at week 12 to calculate the FEV1 AUC for these different time spans: .5 min, 15 min, 1:00 h, 2:00 h, 4:00 h, 6:00 h, 8:00 h, and 11:55 h after the morning dose. The endpoint was the change from baseline (CFB) in FEV1 AUC0-12h following the morning dose at day 1 or week 12, respectively, (defined as the mean FEV1 change from baseline over 5 min to 11 h 55 mins divided by 11 h 50 mins). Where the FEV1 AUC is smaller than at baseline, a negative value can occur.
Time frame: Day 1 and Week 12
Change From Baseline in Forced Expiratory Volume in One Second at All Individual Timepoints
The Forced Expiratory Volume in one second (FEV1) assessments for all individual time points of the serial measurements on day 1 and at week 12 are analyzed. Time points of the serial lung function measurements are 5 min, 15 min, 1:00 h, 2:00 h, 4:00 h, 6:00 h, 8:00 h, and 11:55 h after the morning dose. The table indicates the percent change from baseline (CFB) in FEV1 and standard deviation in brackets. Where the FEV1 is lower than at baseline, a negative percent value can occur.
Time frame: Day 1 and week 12
Mean Trough Forced Expiratory Volume in One Second
Mean trough Forced Expiratory Volume in one second (FEV1) is assessed as the arithmetic mean of two FEV1 measurements, conducted within the last hour of a 24 hour period from a morning dose, either that of day 1 or at week 12 of treatment. The data is reported as the change from baseline (CFB), with the baseline being the arithmetic mean of the two pre-dose measurements (-45 min and -15 min) preceding the serial lung function measurements on Day 1
Time frame: Day 1 and week 12
Change From Baseline in the Health Status Assessed by St. George's Respiratory Questionnaire
The health status, as reported by the patients, is assessed using the St. George's Respiratory Questionnaire (SGRQ). The SGRQ is a 50 item scale assessing symptoms, patient activities and impact of the disease. Scores range from 0 to 100 units, with higher scores indicating more limitations. The assessment is based on total score as well as the percentage of patients with clinically significant improvement at week 12 versus day 1. A clinically meaningful improvement (MCID) in SGRQ is defined as a decrease of 4 or more units of the SGRQ scale in the total score, as compared to baseline (change from baseline).
Time frame: Week 12
Breathlessness Assessed by Transition Dyspnea Index
Breathlessness at week 12 is measured using the interviewer-administered Transition Dyspnea Index (TDI). On day 1, breathlessness is assessed by the interviewer-administered Baseline Dyspnea Index (BDI). The change from BDI to TDI is assessed, with the TDI total score ranging from -9 to +9 units of the scale. The lower the score, the more deterioration in severity of dyspnea. Patients are considered to have clinically significant improvement (MCID) with the TDI score change versus BDI being equal to or greater than 1.
Time frame: Week 12
Change From Baseline in Mean Number of Puffs of Rescue Medication Per Day
Patients report the number of puffs of rescue medication (salbutamol / albuterol) using an electronic diary. The use of rescue medication is analyzed as the change from baseline in the mean daily number of puffs used per patient over the 12 weeks treatment period. The baseline is calculated from the run-in epoch prior to randomization (mean number of puffs per day). A negative number indicates a reduction in the mean daily number of puffs of rescue medication.
Time frame: Baseline and week 12
Change From Baseline in the Percentage of Days Without Rescue Medication Use
Patients report the number of puffs of rescue medication (salbutamol / albuterol) using an electronic diary. The use of rescue medication is analyzed as the change from baseline in the percentage of days without usage of rescue medication over the 12 weeks treatment period. The baseline is calculated as the percentage of days without usage of rescue medication from during the the run-in epoch prior to randomization.
Time frame: Baseline and week 12
Change From Baseline in Daily Symptom Scores
Patients are reporting symptoms by using an electronic diary. The electronic diary has 9 symptom questions each morning and each evening. Each question can be answered with one of four pre-defined answers, corresponding to a unit value of 0-3, where 0 stands for the lowest and 3 for the most severe symptom experience. Symptom scores are calculated as the mean of the combined daily symptom scores (combined from morning and evening scores) for each patient over 12 weeks (Day 1 to week 12). The baseline is calculated from the run-in epoch prior to randomization. The change from baseline in the least squares mean daily symptom scores over the 12 week treatment period is provided. Where the mean daily symptom score over the 12 week treatment period is lower than the baseline, the result is negative. A negative result indicates an improvement in COPD symptom severity.
Time frame: day 1 to week 12
Change From Baseline in the Percentage of Nights With "no Nighttime Awakenings"
Patients are reporting symptoms by using an electronic diary. The electronic diary has 9 symptom questions each morning and each evening. One of the symptom questions of the morning questionnaire relates to the number of awakenings due to COPD symptoms during the previous night. The answer with the lowest symptom score is "no waking due to symptoms." A night with "no nighttime awakening" is defined from diary data as any night where the patient did not wake up due to symptoms. The change from baseline in the percentage of nights with "no nighttime awakening" is calculated from the mean percentage of nights with this answer over the 12 week treatment period, with the baseline being The baseline is calculated from the run-in epoch prior to randomization.
Time frame: Day 1 and week 12
Change From Baseline in the Percentage of Days With "no Daytime Symptoms"
Patients are reporting symptoms by using an electronic diary. The electronic diary has 9 symptom questions each morning and each evening. Each question can be answered with one of four pre-defined answers, corresponding to a unit value of 0-3, where 0 stands for the lowest and 3 for the most severe symptom experience. A day with "no daytime symptoms" is defined from diary data as any day where the patient has recorded in the evening no cough, no wheeze, no production of sputum, and no feeling of breathlessness (other than when running) during the past approximately 12 hours in the evening questionnaire. The change from baseline in the percentage of days with "no daytime symptoms" is calculated from the mean percentage of days with this answer over the 12 week treatment period, with the baseline being. The baseline is calculated from the run-in epoch prior to randomization.
Time frame: Day 1 to week 12
Change From Baseline in Percentage of "Days Able to Perform Usual Daily Activities"
Patients are reporting symptoms by using an electronic diary. The electronic diary has 9 symptom questions each morning and each evening. One of the symptom questions of the evening questionnaire relates to the impact of COPD symptoms on the performance of usual daily activities ("Did your respiratory symptoms stop you performing your usual daily activities today"). The answer with the lowest symptom score is "not at all." A "day able to perform usual daily activities" is defined from diary data as any day where the patient was not prevented from performing their usual daily activities due to respiratory symptoms. The change from baseline in the percentage of "days able to perform usual daily activities" is calculated from the mean percentage of days with this answer over the 12 week treatment period, with the baseline beingThe baseline is calculated from the run-in epoch prior to randomization.
Time frame: Day 1 to week 12
Change From Baseline in Forced Vital Capacity at All Individual Timepoints
The Forced Vital Capacity (FVC)assessments for all individual time points of the serial measurements on day 1 and at week 12 are analyzed. Serial lung function measurements are taken at the following time points following dosing on Day 1 and at week 12: 5 min, 15 min, 1:00 h, 2:00 h, 4:00 h, 6:00 h, 8:00 h, and 11:55 h after the morning dose. For week 12 (day 85), the pre-dose measurements (-45 min and -15 min) and the trough measurements (23:15 h and 23:45 h post-dose) are included. The endpoints are the change from baseline in FVC following the morning dose on Day 1 and at Week 12. Where the FVC at any one timepoint is smaller than at baseline, a negative value can occur.
Time frame: Day 1 and week 12
Change From Baseline in Mean Trough Forced Vital Capacity
Mean trough Forced Vital Capacity (FVC) is assessed as the arithmetic mean of two FVC measurements, conducted within the last hour of a 24 hours period from a morning dose, either that of day 1 or at week 12 of treatment (23:15 h and 23:45 h assessments). The endpoints are the change from baseline in trough FVC on Day 1 and at Week 12, with the mean of the -45 min and -15 min measurements on Day 1 as the baseline.
Time frame: Day 1 and week 12
Change From Baseline in Morning and Nighttime Symptom Scores
Patients are reporting morning and nighttime symptoms by using an electronic diary. The electronic diary has 9 symptom questions each morning and each evening. Each question can be answered with one of four pre-defined answers, corresponding to a unit value of 0-3, where 0 stands for the lowest and 3 for the most severe symptom experience. Morning and nighttime symptoms scores for each patient over 12 weeks are reported and analyzed. Symptom scores are calculated as the mean of the symptom scores (morning symptom scores or nighttime symptom scores, respectively) for each patient over 12 weeks (Day 1 to week 12). The baseline is calculated from the run-in epoch prior to randomization. The outcome is calculated as the change from baseline in the morning and nighttime symptom scores, respectively. A negative number indicates a reduction in the symptom severity and is owed to the calculation of the change from baseline.
Time frame: Day 1 to week 12
| Milestone | NVA237 | Placebo |
|---|---|---|
| Started | 216 | 216 |
| Full analysis set (fas) | 215 | 214 |
| Completed | 209 | 205 |
| Not completed | 7 | 11 |
| Withdrew: Lost to follow-up | 0 | 2 |
| Withdrew: Patient/guardian decision | 7 | 9 |
The standardized Area Under the Curve (AUC) for Forced Expiratory Volume in one second (FEV1) post dosing (FEV1 AUC) is measured at week 12 of treatment. Serial lung function measurements are taken at the following time points following dosing at week 12 to calculate the FEV1 AUC: 5 min, 15 min, 1:00 h, 2:00 h, 4:00 h, 6:00 h, 8:00 h, and 11:55 h after the morning dose. The primary endpoint was the change from baseline in FEV1 AUC0-12h following the morning dose at Week 12 (defined as the mean FEV1 change from baseline (CFB) over 5 min to 11 h 55 mins divided by 11 h 50 mins). Where the FEV1 AUC is smaller than at baseline, a negative value can occur
| Liters | NVA237 | Placebo |
|---|---|---|
| Change From Baseline in Standardized Area Under the Curve for Forced Expiratory Volume in One Second Post Dosing | 0.115 ± 0.0153 | -0.008 ± 0.0153 |
The standardized Area Under the Curve (AUC) for Forced Expiratory Volume in one second (FEV1) post dosing (FEV1 AUC) is assessed at day 1 of treatment. Serial lung function measurements are taken at the following various time points post dosing at day 1 to calculate the FEV1 AUC: 5 min, 15 min, 1:00 h, 2:00 h, 4:00 h, 6:00 h, 8:00 h, and 11:55 h after the morning dose. .The endpoint was the change from baseline (CFB) in FEV1 AUC0-12h following the morning dose at day 1 (defined as the mean FEV1 change from baseline over 5 min to 11 h 55 mins divided by 11 h 50 mins). Where the FEV1 AUC is smaller than at baseline, a negative value can occur.
| Liters | NVA237 | Placebo |
|---|---|---|
| Change From Baseline in Standardized Area Under the Curve (AUC(0-12h)) for Forced Expiratory Volume in One Second Post Dosing | 0.121 ± 0.0096 | 0.003 ± 0.0096 |
The standardized Area Under the Curve (AUC) for Forced Expiratory Volume in one second (FEV1FEV1) is assessed for different time spans (0-4 h, 4-8 h, 8-12 h) within the overall serial measurement post dosing (FEV1 AUCs Time Spans), at day 1 and at week 12 of treatment. Serial lung function measurements are taken at various the following time points post dosing on day 1 and at week 12 to calculate the FEV1 AUC for these different time spans: .5 min, 15 min, 1:00 h, 2:00 h, 4:00 h, 6:00 h, 8:00 h, and 11:55 h after the morning dose. The endpoint was the change from baseline (CFB) in FEV1 AUC0-12h following the morning dose at day 1 or week 12, respectively, (defined as the mean FEV1 change from baseline over 5 min to 11 h 55 mins divided by 11 h 50 mins). Where the FEV1 AUC is smaller than at baseline, a negative value can occur.
| Liters | NVA237 | Placebo |
|---|---|---|
| Day 1 AUC 0-4h (n=215,213) | 0.154 ± 0.0088 | 0.014 ± 0.0088 |
| Week 12 AUC 0-4h (n=215,213) | 0.153 ± 0.0159 | 0.004 ± 0.0159 |
| Day 1 AUC 4-8h (n=213,209) | 0.118 ± 0.0107 | 0.011 ± 0.0109 |
| Week 12 AUC 4-8h (n=213,209) | 0.107 ± 0.0159 | 0.000 ± 0.0158 |
| Day 1 AUC 8-12h (n=212,210) | 0.085 ± 0.0120 | -0.021 ± 0.0120 |
| Week 12 AUC 8-12h (n=212,210) | 0.075 ± 0.0164 | -0.033 ± 0.0164 |
The Forced Expiratory Volume in one second (FEV1) assessments for all individual time points of the serial measurements on day 1 and at week 12 are analyzed. Time points of the serial lung function measurements are 5 min, 15 min, 1:00 h, 2:00 h, 4:00 h, 6:00 h, 8:00 h, and 11:55 h after the morning dose. The table indicates the percent change from baseline (CFB) in FEV1 and standard deviation in brackets. Where the FEV1 is lower than at baseline, a negative percent value can occur.
| Percent | NVA237 | Placebo |
|---|---|---|
| FEV1, day 1, 5 min (n=207,202) | 4.9 ± 8.67 | -0.3 ± 7.07 |
| FEV1, day 1, 15 min (n=209,201) | 9.9 ± 10.05 | 0.3 ± 7.62 |
| FEV1, day 1, 1 h (n=205,205) | 13.9 ± 11.98 | 1.2 ± 9.05 |
| FEV1, day 1, 2 h (n=201,205) | 16.0 ± 14.42 | 2.5 ± 9.80 |
| FEV1, day 1, 4 h (n=199,202) | 12.7 ± 13.39 | 2.2 ± 12.63 |
| FEV1, day 1, 6h (n=197,197) | 10.3 ± 13.82 | 2.2 ± 11.88 |
| FEV1, day 1, 8 h (n=200,189) | 8.9 ± 14.43 | -0.5 ± 12.42 |
| FEV1, day 1, 11 h 55min (n=184,182) | 6.6 ± 13.44 | -1.7 ± 14.03 |
| FEV1, day 85, -45min (n=184,188) | 6.4 ± 17.61 | 1.7 ± 17.95 |
| FEV1, day 85, -15min (n=180,185) | 9.6 ± 18.23 | 2.7 ± 17.82 |
| FEV1, day 85, 5min (n=185,178) | 10.4 ± 18.78 | 1.8 ± 17.22 |
| FEV1, day 85, 15min (n=186,189) | 12.9 ± 20.00 | 2.0 ± 17.08 |
| FEV1, day 85, 1h (n=184,187) | 15.8 ± 20.49 | 1.6 ± 17.37 |
| FEV1, day 85, 2h (n=178,187) | 16.0 ± 20.83 | 2.4 ± 18.52 |
| FEV1, day 85, 4h (n=179,183) | 12.5 ± 19.72 | 3.5 ± 20.25 |
| FEV1, day 85, 6h (n=174,172) | 9.8 ± 18.78 | 2.5 ± 20.84 |
| FEV1, day 85, 8h (n=178,174) | 7.8 ± 18.18 | 0.2 ± 18.86 |
| FEV1, day 85, 11h 55min (n=171,171) | 7.2 ± 19.39 | -2.1 ± 20.07 |
Mean trough Forced Expiratory Volume in one second (FEV1) is assessed as the arithmetic mean of two FEV1 measurements, conducted within the last hour of a 24 hour period from a morning dose, either that of day 1 or at week 12 of treatment. The data is reported as the change from baseline (CFB), with the baseline being the arithmetic mean of the two pre-dose measurements (-45 min and -15 min) preceding the serial lung function measurements on Day 1
| Liters | NVA237 | Placebo |
|---|---|---|
| Day 1 | 0.128 ± 0.0129 | 0.021 ± 0.0130 |
| Week 12 | 0.123 ± 0.0166 | 0.038 ± 0.0166 |
The health status, as reported by the patients, is assessed using the St. George's Respiratory Questionnaire (SGRQ). The SGRQ is a 50 item scale assessing symptoms, patient activities and impact of the disease. Scores range from 0 to 100 units, with higher scores indicating more limitations. The assessment is based on total score as well as the percentage of patients with clinically significant improvement at week 12 versus day 1. A clinically meaningful improvement (MCID) in SGRQ is defined as a decrease of 4 or more units of the SGRQ scale in the total score, as compared to baseline (change from baseline).
| Score | NVA237 | Placebo |
|---|---|---|
| Change From Baseline in the Health Status Assessed by St. George's Respiratory Questionnaire | -6.4 ± 1.08 | -1.2 ± 1.06 |
Breathlessness at week 12 is measured using the interviewer-administered Transition Dyspnea Index (TDI). On day 1, breathlessness is assessed by the interviewer-administered Baseline Dyspnea Index (BDI). The change from BDI to TDI is assessed, with the TDI total score ranging from -9 to +9 units of the scale. The lower the score, the more deterioration in severity of dyspnea. Patients are considered to have clinically significant improvement (MCID) with the TDI score change versus BDI being equal to or greater than 1.
| Score | NVA237 | Placebo |
|---|---|---|
| Breathlessness Assessed by Transition Dyspnea Index | 0.95 ± 0.280 | 0.48 ± 0.277 |
Patients report the number of puffs of rescue medication (salbutamol / albuterol) using an electronic diary. The use of rescue medication is analyzed as the change from baseline in the mean daily number of puffs used per patient over the 12 weeks treatment period. The baseline is calculated from the run-in epoch prior to randomization (mean number of puffs per day). A negative number indicates a reduction in the mean daily number of puffs of rescue medication.
| Number of puffs | NVA237 | Placebo |
|---|---|---|
| Change From Baseline in Mean Number of Puffs of Rescue Medication Per Day | -1.33 ± 0.163 | -0.80 ± 0.160 |
Patients report the number of puffs of rescue medication (salbutamol / albuterol) using an electronic diary. The use of rescue medication is analyzed as the change from baseline in the percentage of days without usage of rescue medication over the 12 weeks treatment period. The baseline is calculated as the percentage of days without usage of rescue medication from during the the run-in epoch prior to randomization.
| percentage of days | NVA237 | Placebo |
|---|---|---|
| Change From Baseline in the Percentage of Days Without Rescue Medication Use | 11.4 ± 1.95 | 7.0 ± 1.97 |
Patients are reporting symptoms by using an electronic diary. The electronic diary has 9 symptom questions each morning and each evening. Each question can be answered with one of four pre-defined answers, corresponding to a unit value of 0-3, where 0 stands for the lowest and 3 for the most severe symptom experience. Symptom scores are calculated as the mean of the combined daily symptom scores (combined from morning and evening scores) for each patient over 12 weeks (Day 1 to week 12). The baseline is calculated from the run-in epoch prior to randomization. The change from baseline in the least squares mean daily symptom scores over the 12 week treatment period is provided. Where the mean daily symptom score over the 12 week treatment period is lower than the baseline, the result is negative. A negative result indicates an improvement in COPD symptom severity.
| Score | NVA237 | Placebo |
|---|---|---|
| Change From Baseline in Daily Symptom Scores | -1.09 ± 0.103 | -0.80 ± 0.104 |
Patients are reporting symptoms by using an electronic diary. The electronic diary has 9 symptom questions each morning and each evening. One of the symptom questions of the morning questionnaire relates to the number of awakenings due to COPD symptoms during the previous night. The answer with the lowest symptom score is "no waking due to symptoms." A night with "no nighttime awakening" is defined from diary data as any night where the patient did not wake up due to symptoms. The change from baseline in the percentage of nights with "no nighttime awakening" is calculated from the mean percentage of nights with this answer over the 12 week treatment period, with the baseline being The baseline is calculated from the run-in epoch prior to randomization.
| Percentage of nights | NVA237 | Placebo |
|---|---|---|
| Change From Baseline in the Percentage of Nights With "no Nighttime Awakenings" | 13.1 ± 1.52 | 9.2 ± 1.54 |
Patients are reporting symptoms by using an electronic diary. The electronic diary has 9 symptom questions each morning and each evening. Each question can be answered with one of four pre-defined answers, corresponding to a unit value of 0-3, where 0 stands for the lowest and 3 for the most severe symptom experience. A day with "no daytime symptoms" is defined from diary data as any day where the patient has recorded in the evening no cough, no wheeze, no production of sputum, and no feeling of breathlessness (other than when running) during the past approximately 12 hours in the evening questionnaire. The change from baseline in the percentage of days with "no daytime symptoms" is calculated from the mean percentage of days with this answer over the 12 week treatment period, with the baseline being. The baseline is calculated from the run-in epoch prior to randomization.
| Percentage of days | NVA237 | Placebo |
|---|---|---|
| Change From Baseline in the Percentage of Days With "no Daytime Symptoms" | 3.6 ± 1.17 | 2.6 ± 1.18 |
Patients are reporting symptoms by using an electronic diary. The electronic diary has 9 symptom questions each morning and each evening. One of the symptom questions of the evening questionnaire relates to the impact of COPD symptoms on the performance of usual daily activities ("Did your respiratory symptoms stop you performing your usual daily activities today"). The answer with the lowest symptom score is "not at all." A "day able to perform usual daily activities" is defined from diary data as any day where the patient was not prevented from performing their usual daily activities due to respiratory symptoms. The change from baseline in the percentage of "days able to perform usual daily activities" is calculated from the mean percentage of days with this answer over the 12 week treatment period, with the baseline beingThe baseline is calculated from the run-in epoch prior to randomization.
| Percentage of days | NVA237 | Placebo |
|---|---|---|
| Change From Baseline in Percentage of "Days Able to Perform Usual Daily Activities" | 5.2 ± 1.61 | 0.9 ± 1.65 |
The Forced Vital Capacity (FVC)assessments for all individual time points of the serial measurements on day 1 and at week 12 are analyzed. Serial lung function measurements are taken at the following time points following dosing on Day 1 and at week 12: 5 min, 15 min, 1:00 h, 2:00 h, 4:00 h, 6:00 h, 8:00 h, and 11:55 h after the morning dose. For week 12 (day 85), the pre-dose measurements (-45 min and -15 min) and the trough measurements (23:15 h and 23:45 h post-dose) are included. The endpoints are the change from baseline in FVC following the morning dose on Day 1 and at Week 12. Where the FVC at any one timepoint is smaller than at baseline, a negative value can occur.
| Liters | NVA237 | Placebo |
|---|---|---|
| FVC, day 1, 5 min (n=214,211) | 0.120 ± 0.0129 | -0.014 ± 0.0131 |
| FVC, day 1, 15 min (n=214,213) | 0.233 ± 0.0155 | 0.005 ± 0.0157 |
| FVC, day 1, 1 h (n=215,211) | 0.304 ± 0.0175 | 0.041 ± 0.0176 |
| FVC, day 1, 2 h (n=211,211) | 0.322 ± 0.0193 | 0.060 ± 0.0191 |
| FVC, day 1, 4 h (n=209,208) | 0.247 ± 0.0196 | 0.048 ± 0.0195 |
| FVC, day 1, 6 h (n=208,205) | 0.225 ± 0.0219 | 0.051 ± 0.0220 |
| FVC, day 1, 8 h (n=209,205) | 0.200 ± 0.0228 | -0.002 ± 0.0232 |
| FVC, day 1, 11 h 55min (n=203,202) | 0.147 ± 0.0242 | -0.017 ± 0.0243 |
| FVC, day 85, -45 min (n=207,204) | 0.123 ± 0.0248 | 0.008 ± 0.0246 |
| FVC, day 85, -15 min (n=208,204) | 0.146 ± 0.0241 | 0.010 ± 0.0239 |
| FVC, day 85, 5 min (n=214,211) | 0.177 ± 0.0247 | 0.001 ± 0.0251 |
| FVC, day 85, 15 min (n=214,213) | 0.219 ± 0.0261 | -0.003 ± 0.0259 |
| FVC, day 85, 1 hr (n=215,211) | 0.267 ± 0.0261 | 0.010 ± 0.0260 |
| FVC, day 85, 2 hr (n=211,211) | 0.275 ± 0.0277 | 0.024 ± 0.0271 |
| FVC, day 85, 4 hr (n=209,208) | 0.204 ± 0.0281 | 0.035 ± 0.0278 |
| FVC, day 85, 6 hr (n=208,205) | 0.185 ± 0.0278 | 0.016 ± 0.0278 |
| FVC, day 85, 8 hr (n=209,205) | 0.152 ± 0.0264 | -0.015 ± 0.0266 |
| FVC, day 85, 11 hr 55min (n=203,202) | 0.135 ± 0.0290 | -0.045 ± 0.0288 |
| FVC, day 85, 23 hr 15min (n=210,204) | 0.207 ± 0.0289 | 0.066 ± 0.0284 |
| FVC, day 85, 23 hr 45min (n=213,208) | 0.228 ± 0.0292 | 0.095 ± 0.0290 |
Mean trough Forced Vital Capacity (FVC) is assessed as the arithmetic mean of two FVC measurements, conducted within the last hour of a 24 hours period from a morning dose, either that of day 1 or at week 12 of treatment (23:15 h and 23:45 h assessments). The endpoints are the change from baseline in trough FVC on Day 1 and at Week 12, with the mean of the -45 min and -15 min measurements on Day 1 as the baseline.
| Liters | NVA237 | Placebo |
|---|---|---|
| Day 1 | 0.249 ± 0.0225 | 0.078 ± 0.0227 |
| Week 12 | 0.210 ± 0.0277 | 0.080 ± 0.0276 |
Patients are reporting morning and nighttime symptoms by using an electronic diary. The electronic diary has 9 symptom questions each morning and each evening. Each question can be answered with one of four pre-defined answers, corresponding to a unit value of 0-3, where 0 stands for the lowest and 3 for the most severe symptom experience. Morning and nighttime symptoms scores for each patient over 12 weeks are reported and analyzed. Symptom scores are calculated as the mean of the symptom scores (morning symptom scores or nighttime symptom scores, respectively) for each patient over 12 weeks (Day 1 to week 12). The baseline is calculated from the run-in epoch prior to randomization. The outcome is calculated as the change from baseline in the morning and nighttime symptom scores, respectively. A negative number indicates a reduction in the symptom severity and is owed to the calculation of the change from baseline.
| Score | NVA237 | Placebo |
|---|---|---|
| Daytime total symptom score (n=207,195) | -0.86 ± 0.097 | -0.61 ± 0.100 |
| Nighttime total symptom score (n=208,200) | -1.03 ± 0.101 | -0.76 ± 0.102 |
Non-serious events are listed at a 0.9% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| NVA237 | — | 9/216 (4.2%) | 88/216 (40.7%) |
| Placebo | — | 5/214 (2.3%) | 81/214 (37.9%) |
| Event | NVA237 | Placebo |
|---|---|---|
| CHRONIC OBSTRUCTIVE PULMONARY DISEASERespiratory, thoracic and mediastinal disorders | 3/216 | 3/214 |
| SPINAL COMPRESSION FRACTUREInjury, poisoning and procedural complications | 0/216 | 1/214 |
| HAEMOPTYSISRespiratory, thoracic and mediastinal disorders | 0/216 | 1/214 |
| PULMONARY MASSRespiratory, thoracic and mediastinal disorders | 0/216 | 1/214 |
| ACUTE MYOCARDIAL INFARCTIONCardiac disorders | 1/216 | 0/214 |
| ANGINA PECTORISCardiac disorders | 1/216 | 0/214 |
| CELLULITISInfections and infestations | 1/216 | 0/214 |
| HERPES SIMPLEXInfections and infestations | 1/216 | 0/214 |
| OPHTHALMIC HERPES ZOSTERInfections and infestations | 1/216 | 0/214 |
| PNEUMONIAInfections and infestations | 1/216 | 0/214 |
| Event | NVA237 | Placebo |
|---|---|---|
| CHRONIC OBSTRUCTIVE PULMONARY DISEASERespiratory, thoracic and mediastinal disorders | 43/216 | 43/214 |
| HEADACHENervous system disorders | 2/216 | 7/214 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 7/216 | 3/214 |
| COUGHRespiratory, thoracic and mediastinal disorders | 6/216 | 6/214 |
| NASAL CONGESTIONRespiratory, thoracic and mediastinal disorders | 0/216 | 5/214 |
| NASOPHARYNGITISInfections and infestations | 5/216 | 2/214 |
| BACK PAINMusculoskeletal and connective tissue disorders | 5/216 | 1/214 |
| OROPHARYNGEAL PAINRespiratory, thoracic and mediastinal disorders | 5/216 | 1/214 |
| BRONCHITISInfections and infestations | 0/216 | 4/214 |
| DIARRHOEAGastrointestinal disorders | 2/216 | 3/214 |
| Age, Continuous(Years) | NVA237 | Placebo | Total |
|---|---|---|---|
| Mean | 63.9 ± 8.55 | 64.2 ± 8.41 | 64.1 ± 8.47 |
| Sex: Female, Male(Participants) | NVA237 | Placebo | Total |
|---|---|---|---|
| Female | 88 | 90 | 178 |
| Male | 128 | 126 | 254 |
The record gives a start of Nov 2012, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2015, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Glycopyrrolate
Pulmonary Disease, Chronic Obstructive →